Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial

The American Journal of GASTROENTEROLOGY INTRODUCTION Chemoprevention of sporadic colorectal adenomatous polyps is a promising approach to controlling colorectal cancer and its attendant morbidity and mortality. Worldwide, the highest rates of colorectal cancer occur in Australia and its neighbor New Zealand, western Europe, southern Europe, and North America, Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial

[1]  J. Baron,et al.  Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence—Data from a Randomized Clinical Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[2]  A. Zauber,et al.  Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial , 2009, Cancer Prevention Research.

[3]  Elizabeth L. Barry,et al.  Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. , 2009, Journal of the National Cancer Institute.

[4]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[5]  R. Hunt,et al.  Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint , 2008, Cancer Epidemiology Biomarkers & Prevention.

[6]  A. Zauber,et al.  Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial , 2008, Cancer Prevention Research.

[7]  B. Levin,et al.  Chemoprevention of colorectal neoplasia: the potential for personalized medicine. , 2008, Gastroenterology.

[8]  Elizabeth L. Barry,et al.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.

[9]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[10]  J. Baron,et al.  A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. , 2006, Gastroenterology.

[11]  S. Solomon,et al.  Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.

[12]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[13]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[14]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[15]  J. Little,et al.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. , 2003, Gastroenterology.

[16]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[17]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[18]  G. Meijer.  GLOBOCAN 1: Cancer Incidence and Mortality Worldwide. , 2000 .

[19]  F. Sinicrope,et al.  Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. , 1999, Gastroenterology.

[20]  G. Beck,et al.  Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. , 1999, The New England journal of medicine.

[21]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[22]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[23]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[24]  G. Kelloff,et al.  Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. , 1993, Carcinogenesis.

[25]  F. DeRubertis,et al.  Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. , 1992, Carcinogenesis.

[26]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[27]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[28]  G. Koch,et al.  Interpretation of statistical methodology associated with maintenance trials. , 1984, The American journal of medicine.

[29]  J. Salomon,et al.  Mechanism of inhibition of tumour growth by aspirin and indomethacin. , 1978, British Journal of Cancer.

[30]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[31]  S. Winawer.  Screening of colorectal cancer: progress and problems. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.